Human Immunology Registry – A Research Milestone

SALT LAKE CITY--(BUSINESS WIRE)--RemedyMD (www.RemedyMD.com), the leading provider of disease registry software, today announced the first nationwide human immunology registry for infectious disease research. The new registry was developed to help clinicians and researchers better understand the human immune response to emerging and re-emerging infectious diseases.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies”

Details about the registry:

http://www.remedymd.com/cer100/human_immunology.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s human immunology registry will help researchers develop new vaccines to protect against infectious diseases such as:

Influenza
Dengue fever
Anthrax
Hepatitis C

and help researchers understand how the immune system develops its own protections and how harmless microorganisms in the lungs, intestines and other mucosal surfaces protect against harmful microbes that enter the body through these sites.

The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies,” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new human immunology registry leverages existing clinical and EHR data and includes a comprehensive set of electronic data collection (EDC) forms that are specific to immunology research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying novel conclusions as they search for the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of immunology researchers. All institutions involved in comparative effectiveness research are invited to visit: http://www.remedymd.com/cer100/human_immunology.html.

RemedyMD Resources:

Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit.html

Ways to leverage Human Immunology Registry: http://www.remedymd.com/cer100/human_immunology.html

Comparative Effectiveness Research: www.remedymd.com/cer_home.html

Disease Registry Software: www.remedymd.com/registries_home.html

About RemedyMD

RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.